Anne Phelan
Directeur Technique/Scientifique/R&D chez BENEVOLENTAI
Postes actifs de Anne Phelan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BENEVOLENTAI | Directeur Technique/Scientifique/R&D | 01/11/2019 | - |
BenevolentAI Cambridge Ltd.
 BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 03/01/2019 | - |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Directeur Technique/Scientifique/R&D | 01/09/2019 | - |
Historique de carrière de Anne Phelan
Anciens postes connus de Anne Phelan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/01/2018 | 01/11/2018 |
| PFIZER, INC. | Corporate Officer/Principal | 01/04/2014 | 01/10/2015 |
Formation de Anne Phelan
| University of Liverpool | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 6 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Commercial Services | 2 |
| Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BENEVOLENTAI | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Anne Phelan
- Expérience
